Mike joined EyeBio as Chemistry, Manufacturing, and Control (CMC) Lead, Drug Development in 2023. In this capacity, Mike is responsible for the development of all CMC related aspects of the pipeline post candidate confirmation.

Bringing over 25 years of experience in the biotechnology industry, with multiple successful IND and MAA/BLA submissions across different biological modalities, Mike is an expert in both CMC and drug development.

Previously, Mike was Head of Analytical Services at Lonza Biologics, VP of Protein Sciences at F-star, and has also worked to support a diverse range of biotechnology companies with Protein Science, CMC, and IND and BLA projects including recombinant proteins, mAbs, Fc fusion proteins, bi-specific antibodies, vaccines, and ATMPs.

Mike received B.Sc. in Biochemistry from Lancaster University.

Frances joined EyeBio as Head of Clinical Operations in September 2022. In this role, Frances is responsible for clinical operations worldwide to ensure the successful delivery of clinical studies.

Frances has a 30-year career in clinical development. Prior to joining EyeBio, Frances worked in clinical research developing products in oncology, virology, and ophthalmology for a range of companies. Earlier in her career, Frances worked at Roche for over 10 years and participated in the successful filing of Roferon^®, Neupogen^®, and MabThera^®. Following Roche, she subsequently joined Eyetech and was part of the team developing Macugen.

In recent years Frances has supported many studies to develop products in ophthalmology ranging from first in human Phase I studies to large global Phase III studies.

Laura Kupsch joined EyeBio as the Vice President Quality Assurance in 2023. She is responsible for providing strategic direction for the company’s quality operations including compliance of contract organizations and the development, implementation, and maintenance of the overall Quality Management System in accordance with appropriate regulatory requirements.

Laura has more than 25 years of GxP industry experience, including several years at emerging companies focused on retinal diseases. In her previous role as Vice President, Quality Assurance, at Passage Bio, she led a team responsible for ensuring GxP compliance of all product development and testing.

Laura received her Doctorate in Regulatory Sciences from the University of Southern California, as well as a Master of Science degree from Temple University and an MBA from Marist College.

Divya joined EyeBio as Senior Vice President of Clinical Development. She is responsible for the company’s clinical development strategy and execution. 

Prior to joining EyeBio, Divya held various roles at the United Kingdom’s (UK) National Institute for Health Research (NIHR) beginning in 2007. Her most recent role at NIHR was the Clinical Research Network’s Director of Business Development and Marketing, where she led a team responsible for increasing investment into UK-based health and social care research from both non-commercial and commercial research sponsors. 

In 2020, Divya was seconded to the UK Vaccines Taskforce (VTF), which was set up in response to the COVID-19 pandemic to lead the UK’s search for a safe and effective vaccine. In that capacity she was responsible for supporting global pharmaceutical companies’ efforts to rapidly generate the evidence required for marketing authorization of COVID-19 vaccines and played a pivotal role in conceptualizing and developing the National Health Service (NHS) Vaccine Research Registry. 

Divya holds a B.Sc. in Psychology from Royal Holloway at the University of London, and was awarded an India academic scholarship to complete a MRes degree at the University of Birmingham, UK.  

Eric joined EyeBio in 2023 as Senior Vice President of Biology. He is responsible for pre-clinical research and development as well as pipeline expansion.

Prior to EyeBio, Eric was an Assistant Professor of Ophthalmology at the Schepens Eye Research Institute of Mass Eye and Ear and Harvard Medical School, where his research has focused on the biology of vascular endothelial growth factor (VEGF) and its role in the pathogenesis of neuro-vascular diseases of the eye and developing novel therapeutics for these diseases.

Previously, Eric was involved in the discovery of therapeutic targets and drug development for age-related macular degeneration (AMD) and diabetic retinopathy as a lecturer associated with the late Professor David Shima at UCL Institute of Ophthalmology in London through research collaborations with GSK. Before returning to academia, Eric was a Senior Scientist and later Associate Director of Drug Discovery at Eyetech Pharmaceuticals.

Eric received his B.A. in Biology and B.A./M.A. in Biotechnology from Boston University and his Ph.D. in Cell and Developmental Biology from Harvard Medical School. Eric completed his post-doctoral research fellowship in vascular biology at the Schepens Eye Research Institute.

Paul joined EyeBio as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). He is responsible for early candidate selection and development of EyeBio’s large-molecule portfolio.

Paul has more than 35 years of experience in the biotechnology industry. With over 50 peer-reviewed publications, he is an expert in antibody drug development and expression. Previously, Paul was Senior Director and Head of Antibody Biology at UCB, where he was responsible for the company’s early antibody pipeline and oversaw the transition of UCB’s novel biological entities (NBEs) from the research stage into development. While at UCB, Paul was actively involved in the development of both Evenity^® (romosozumab) and Bimzelx^® (bimekizumab).

Paul received B.Sc. in Biochemistry from Southampton University, and he completed his Ph.D. at Sheffield University.